Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exercise and Rivastigmine in Alzheimer's Disease
NCT01183806Phase 3Completed
- Sponsor
- Universidade Federal da Bahia
- Start
- Jul 2010
- Primary completion
- Jan 2012
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivastigmine in Alzheimer's disease (AD), sponsored by Universidade Federal da Bahia. Primary endpoint: Quality of Life in Alzheimer's Disease at 6 months. Started Jul 2010; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01183806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183806.